Dr. Stefan Kauschke is a Senior Principle Scientist in the External Innovation Group in the Department of CardioMetabolic Diseases Research at Boehringer Ingelheim, Biberach, Germany.
He was trained as a biochemist at the Leibniz University Hannover as well as the Medical University Hannover, Germany. Before receiving his M.Sc. in Biochemistry, he did research internships at the Max-Planck-Institute of Biochemistry, Munich as well as the University of North Carolina, Chapel Hill.
To pursue further scientific training and to extend his experiences to a pharmaceutical context, in 1998 he then moved to the Department of Cardiovascular Research at Bayer Pharmaceuticals in Wuppertal where he investigated aspects of collagen metabolism in the context of liver fibrosis. For this work, in the year 2000, he then received his Ph.D. from the Leibniz University Hannover.
In 2000, Dr. Kauschke joined the Group of CardioMetabolic Diseases Research at Boehringer Ingelheim where he worked as a postdoctoral fellow with an initial focus on identifying novel targets and mechanisms in type 2 diabetes.
Dr. Kauschke was then promoted to a head of laboratory in 2002, and together with his team, he worked on the validation of novel target genes for type 2 diabetes, obesity and lipid disorders. For several of these new therapeutic concepts, together with a team of scientists of other disciplines (in vivo Pharmacology, Chemistry, Drug Discovery Support, Structural Research) he could identify and advance novel drug candidates as potential future therapeutics through different stages of drug discovery. In addition, Dr. Kauschke was involved over many years in the evaluation of a multitude of external licensing opportunities.
Joining the External Innovation Group in 2017, his current focus is on the identification and evaluation of external research opportunities, establishing and steering scientific relations, academic collaborations as well as research consortia in the areas of Non-Alcoholic Steato-Hepatitis (NASH), Retinopathies as well as Obesity / Type 2 Diabetes complementing the in-house research activities in the Department of CardioMetabolic Diseases Research.